E. A. van Vliet, E. Aronica, A. Vezzani, T. Ravizza (2018) Neuropathology and Applied Neurobiology 44, 91-111 Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies Accumulating evidence indicates an important pathophysiological role of brain inflammation in epilepsy. In this review, we will provide an update of specific inflammatory pathways that have been proposed to be crucial in the underlying molecular mechanisms of epilepsy, including the interleukin-1 receptor/toll-like receptor signalling, cyclooxygenase-2, tumour necrosis factor-alpha, complement signalling and chemokines.
Introduction
Inflammation refers to the complex biological response of tissues against infections or sterile (noninfectious) injuries, it is closely associated with the activation of both innate and adaptive (i.e. lymphocytes) immune cells. It represents a key homeostatic mechanism of the body's defence, which is crucial for activating mechanisms for tissue repair, via the production of a large array of inflammatory cytokines and related effector molecules.
A novel emerging concept in inflammation is the specific interaction between the innate immune system and injured brain tissue, known as neuroinflammation. Although neuroinflammation currently lacks a consensus definition, in general it can be seen as the biosynthesis and release of molecules with inflammatory properties by resident cells of the brain, including activated microglia and astrocytes, neurons, endothelial cells of the blood-brain barrier (BBB), and blood-born macrophages [1] .
Neuroinflammation is not only triggered in response to 'classical' factors (i.e. infections, autoimmunity, toxins), but also by factors that lead to an increase in neuronal activity, including epileptic seizures. Recently, the term 'neurogenic neuroinflammation' was proposed to describe neuroinflammatory mechanisms evoked by neuronal activity [2] . This process may be homeostatic thus enabling the brain to cope with enhanced metabolic demands such as during seizures. However, it can become maladaptive when it is not properly resolved or when it spreads to remote sites, thus contributing to the pathogenesis of the disease.
A notable finding is that the inflammatory mediators released by the resident brain cells (Figure 1 ) during epileptic activity (i.e. cytokines, chemokines, alarmins/danger signals, prostaglandins, complement factors) are not only effectors molecules of the immune system promoting local inflammation but also function as neuromodulators directly affecting neuronal function and excitability [3] . Indeed, specific inflammatory molecules were reported to significantly contribute to the mechanisms of seizure generation, to epileptogenesis and to drug resistance in experimental models [4] [5] [6] .
Here, we provide a comprehensive review about the current state of knowledge regarding neuroinflammatory pathways in epilepsy. Several reviews have appeared the last years on this topic. However, not much attention has been paid to the role of neuroinflammatory pathways as biomarkers or as treatment targets in both preclinical and clinical studies. Therefore, we specifically focus on pathways which were found to be deregulated in preclinical models of epilepsy as well as in brain specimens from human drug-resistant epilepsies. We describe their cellular sources and targets, their impact on seizure onset, recurrence and epileptogenesis. Furthermore, we discuss their role as potential biomarkers, and the opportunities for novel therapeutic interventions to control drug-resistant seizures or to attain disease-modifying effects.
A literature search was performed using PubMed (https://www.ncbi.nlm.nih.gov/pubmed) with (a combination of) the following keywords: brain, blood, plasma, serum, biomarker, inflammation, inflammatory, Figure 1 . Inflammatory mediators released in epileptogenic brain tissue. A number of inflammatory mediators (i.e. cytokines, chemokines, alarmins/danger signals, prostaglandins, complement factors) are released by brain resident cells during seizures or after epileptogenic events. These molecules promote the activation of inflammatory pathways in neurons, glia and the blood-brain barrier (BBB) but they can also directly affect neuronal excitability by rapid post-transcriptional effects on receptors and ion channels. Blood leucocytes may contribute to increase the levels of inflammatory molecules in brain. These mediators and their signalling pathways may represent novel therapeutic targets for decreasing established seizures or attaining antiepileptogenesis and disease modification effects. Since some mediators are also measurable in blood, they may be validated as noninvasive biomarkers of epilepsy. 
IL-1R/toll-like receptor signalling
The IL-1R/toll-like receptor (TLR) pathway is a crucial upstream signal promoting the activation of the innate immune system and the associated inflammatory response. Beside its classical role in the mechanisms of pathogen recognition and subsequent pathogen removal from tissue [7, 8] , this signalling pathway can also be activated by pro-inflammatory mediators or damage-associated molecular pattern motifs expressed by danger signals which are endogenous molecules released by injured or activated cells.
Expression studies
Experimental models IL-1R type 1 and TLR4 and their prototypical endogenous ligands, [i.e. the proinflammatory cytokine interleukin(IL)-1b and the danger signal HMGB1 respectively] are induced in resident brain cells following various experimental epileptogenic insults such as SE, stroke, neurotrauma, CNS infection, as well as during seizure recurrence [9] . Using rodent models of SE in which epileptogenesis is triggered by electrical stimulation or chemoconvulsants, it has been shown that the level of IL-1b mRNA in the hippocampus, which is barely detectable in the healthy brain, is rapidly (≤30 min) and persistently increased after SE induction [10] [11] [12] . The anti-inflammatory counterpart of IL-1b [i.e. IL-1 receptor antagonist (ra), a naturally occurring IL-1b antagonist] was induced in the brain several hours after IL-1b and never in excess to IL-1b [10] , thus indicating that the effects of IL-1b upon its production in the brain are not rapidly and effectively controlled. Long-lasting induction of IL-1b has also been described in the hippocampus of immature rats that have developed epilepsy after exposure to prolonged febrile seizures [13] .
Immunohistochemical studies have shown that IL-1b is strongly induced in activated microglia and astrocytes during the acute phase of SE and in the chronic phase of spontaneous seizures in brain areas involved in seizure generation and propagation [14, 15] . This expression pattern persists during epileptogenesis in the absence of ongoing seizure activity and it is mainly sustained by astrocytes [14] . IL-1R1 is up-regulated in neurons and astrocytes [14, 16] suggesting that the released cytokine exerts both autocrine and paracrine actions. IL-1b and IL-1R1 are expressed during epileptogenesis in both the perivascular astrocytes and endothelial cells of the BBB, often in association with BBB leakage and neuronal damage [14] , suggesting that IL-1b/IL-1R1 axis may contribute to these pathological changes.
HMGB1 is a chromatin-binding protein that, under physiological conditions, regulates gene transcription [17, 18] . Following pathophysiological cell activation or injury and upon inflammasome activation, HMGB1 rapidly undergoes nucleus-to-cytoplasm translocation, a step required for its cellular release and the consequent biological effects [19] . We recently showed that HMGB1 progressively translocates in the cytoplasm of activated astrocytes and to a lesser extent in microglia, neurons and endothelial cells of the BBB in adult rats exposed to SE during disease development [20] . As for IL-1b, these changes do not solely reflect ongoing seizure activity since they first occur before the onset of spontaneous seizures [20] . Upon its release, HMGB1 activates TLR4 and the Receptor for Advanced Glycation End products. These receptors are rapidly and lastingly induced in neurons and activated astrocytes after epileptogenic insults in rodent epileptogenic brain areas [21] [22] [23] [24] [25] .
Human studies Experimental data have been corroborated by neuropathological evidence of IL-1R/ TLR signalling activation in brain specimens resected at surgery from patients with drug-resistant epilepsy [26, 27] . Thus, IL-1b/ILR1 and HMGB1/TLR4 axes, and their key signalling molecules, have been studied by immunohistochemistry and biochemical methods in low-grade epilepsy-associated glioneuronal tumours [83] (GNT) (ganglioglioma, dysembryoplastic neuroepithelial tumours) [28, 29] , malformations of cortical development (focal cortical dysplasia, tuberous sclerosis) [28, [30] [31] [32] [33] , temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) [14, 21, [34] [35] [36] ] and Rasmussen's encephalitis [37, 38] . Interestingly, the number of IL-1b-and IL-1R1-positive neurons in GNTs was positively correlated with the frequency of seizures, whereas the number of IL-1ra-positive neurons and astrocytes was negatively correlated with the duration of epilepsy prior to surgery [28] , therefore establishing a potential pathogenic link between IL-R1/TLR4 signalling activation and lesion's epileptogenicity. IL-1b expression in tumoral and peritumoral cortices was positively associated with the preoperative seizure frequency and epilepsy duration [29] . The activation of the TLR4 and IL-1R1 signalling is further supported by an increased expression of IL-1R-associated kinase 1 and TNF receptor-associated factor 6 signalling molecules [29, 32, 36] . In all clinical cases, the resident brain cells are major common contributors to the activation of this pathway. Notably, HMGB1 cytoplasmatic staining, indicative of its translocation from nuclei, was increased in neurons and astrocytes in autoptic hippocampal specimens from SE patients [39] , thus confirming the findings in SE-exposed rats.
The activation of TLR4 and IL-1R1 signalling in human epilepsy is supported by gene expression analyses [40] [41] [42] . In particular, the hippocampal level of the TLR4 gene in patients with TLE positively correlated with the frequency of spontaneous seizures before surgery; conversely, there was a negative correlation RNA interference against CCR5
KA-induced SE in rats 4 months before KA Delay in SE onset; ↓ SE severity; ↓ Recovery time [143] IL-1R, interleukin-1 receptor; TLR, toll-like receptor; IL-1ra, IL-1R antagonist; Bic, bicuculline; GAERS, genetic absence epilepsy rats from Strasbourg; LPS, lipopolysaccharide; KA, kainic acid; MES, maximal electroshock; PTZ, pentylenetetrazol; SE, status epilepticus; SRS, spontaneous recurrent seizures; HMGB1, high mobility group box 1; CCR, C-C chemokine receptor; COX-2 cyclooxygenase-2; CCL2, chemokine C-C motif ligand 2.
between the expression of activating transcription factor 3, which downregulates TLR4 and seizure frequency [35] . The evidence that the IL-1R/TLR signalling pathway is activated in the epileptogenic area of patients with structural/lesional drug-resistant epilepsies of different aetiologies, and the correlation between signalling activation and clinical variables, suggests the need for further preclinical studies on the pathophysiological consequences of this activation.
Role of IL-1R/TLR signalling in seizure mechanisms
The contribution of IL-1R1/TLR4 signalling to seizures was shown by the exacerbation of seizures occurring when IL-1b or HMGB1 were injected into the brain before the animal was exposed to a convulsive challenge. Accordingly, the frequency of established seizures was drastically reduced by pharmacological interventions preventing or reversing the signalling activation in the brain (Table 1) . Thus, IL-1b injection Electrically induced SE in rats 3-4 months post-SE for 2 weeks ↑ Number SRS in 50% of the rats [99] SC-51089 (EP1 antagonist)
Electrical kindling in mice 1 h prior kindling ↓ Seizure severity [101] IL-1R, interleukin-1 receptor; TLR, toll-like receptor; IL-1ra, IL-1R antagonist; KA, kainic acid; PTZ, pentylenetetrazol; SE, status epilepticus; SRS, spontaneous recurrent seizures; HMGB1, high mobility group box 1; COX-2, cyclooxygenase-2.
in rodent brains shortly before kainic acid (KA) or bicuculline application resulted in pro-convulsive effects mediated by IL-1R1 [43] [44] [45] , whereas the intracerebral injection of IL-1ra mediated powerful anticonvulsive effects [43, 44] . In accordance, mice overexpressing IL1ra in astrocytes showed a reduced susceptibility to evoked seizures [44] . IL-1b acting on IL-1R1 also lowered core temperature threshold required to induce seizures in a postnatal (PN) day 14 mouse model of febrile convulsions [46] . Since IL-1ra inhibits all IL-1b effects, these data highlight the important contribution of brain IL-1b to seizures. Recently, the release of HMGB1 from neurons and glia was identified as a molecular event that, together with IL-1b [21, 47, 48] , lowers seizure threshold, and HMGB1 effects were mediated by neuronal TLR4 [21, 48] . The redox state of the extracellular milieu is a key factor determining the biological effects of HMGB1: the disulphide (partially oxidized) isoform of HMGB1 activates TLR4 and promotes seizures [47] , whereas the reduced isoform has chemoattractive properties [49] .
Pharmacological or genetic interference with the IL-1R1/TLR4 signalling provided additional demonstration of its involvement in seizure mechanisms (Table 1) . Thus, the blockade of IL-1b biosynthesis with IL-1b converting enzyme/Caspase-1 inhibitors (Pralnacasan, VX-765) [5, 50, 51] or the inactivation of HMGB1's action by its broad spectrum receptor antagonist BoxA or by selective TLR4 antagonists, significant delayed seizure onset and reduced seizure frequency induced by KA or bicuculline in rodents [21] . Similar results were obtained using mice lacking Caspase-1 or IL-1r1 or TLR4 genes, thus reinforcing the pharmacological data [5, 21, 44, 48] . Moreover, the systemic administration of VX-765 in genetic absence epilepsy rats from Strasbourg, a rat model of absence seizures, significantly reduced the number and duration of spike-and-waves discharges [52] . The administration of an inactivating anti-HMGB1 monoclonal antibody attenuated seizures induced either by maximal electroshock or systemic injections of PTZ [53] . These rapid effects (<10 min) are compatible with the activation of fast onset, nontranscriptional pathways. In this respect, the IL-1b-and 59, 60] . Intracerebroventricular injection of a synthetic miR-146a mimic significantly reduced neuronal excitability and acute seizures in mice [25] .
A key player in IL-R1/TLR4 signalling is the inflammasome, an intracellular multiprotein complex mediating caspase-1 activation, which is instrumental for the cellular release of IL-1b and HMGB1 [61] . Activation of microglial P2X7 receptors, an ATP-gated ionotropic purinergic receptor, is pivotal for the assembly of the inflammasome. P2X7 receptors are increased in experimental and human epilepsy, and their antagonism significantly reduces SE and spontaneous seizures in animal models (reviewed in [62] ).
Role of IL-1R/TLR signalling in epileptogenesis
The involvement of IL-1R/TLR pathway in seizure generation in the acute models fostered additional investigation of its potential role in epileptogenesis. This aspect has been addressed by: (i) investigating the effect of selective caspase-1 inhibition on the rate of hippocampal-kindling development (Table 2) ; (ii) pharmacological or epigenetic interference during the period spanning between the primary injury (usually SE) and the predicted time of disease onset, or transiently after epilepsy onset (Table 2) . After stopping the treatment, the onset of epilepsy, spontaneous seizure frequency, neuronal cell loss and comorbidities were measured; (iii) evaluating epilepsy development in transgenic mice lacking specific signalling molecules.
IL-1b synthesis inhibition by VX-765 during rat hippocampal kindling prevented the occurrence of stage 5 seizures without affecting afterdischarge duration [63] . Kindling re-testing 24 h after its completion, in the absence of treatment, showed persistent lack of generalized seizures [63] . These data suggest that caspase-1 inhibition interferes with epileptogenic mechanisms. Transient pharmacological blockade of the IL-1b/IL-1R1 axis in adult rats during SE-induced epileptogenesis was neuroprotective without modifying disease onset or early spontaneous seizures [64] . However, the blockade of IL-1b/IL-1R1 axis alone was insufficient to prevent the TLR4 signalling activation [64] which contributes per se to epileptogenesis [48] . Thus, antiepileptogenic and disease-modifying effects were tested by targeting simultaneously the IL-1R1/TLR4 signalling using a drug combination. Two different treatment protocols were used: (i) adult rats exposed to electrical SE were administered with human recombinant IL-ra (anakinra), BoxA (HMGB1 antagonist) and ifenprodil (NR2B-NMDAR antagonist) during epileptogenesis; (ii) adult mice exposed to intraamygdala KA-induced SE were treated for 2 weeks with VX-765 (caspase-1 inhibitor) and Cyanobacterial Lipopolysaccharide (LPS), a TLR4 antagonist, at epilepsy onset (after the first two spontaneous seizures). Both treatment protocols, although transiently applied, blocked the progression in seizure frequency resulting in up to 90% seizure reduction in the chronic epilepsy phase as compared to vehicle-treated epileptic animals [20, 25] . Similar therapeutic effects were attained by injecting miR-146a mimic in the mouse model at epilepsy onset [25] or administering an anti-HMGB1 monoclonal antibody in mice during epileptogenesis [53] . Accordingly, mice lacking the TLR4 gene showed reduced spontaneous seizures recurrence vs. wild-type mice, in the absence of changes in SE severity or duration, supporting the involvement of this receptor in epileptogenesis [48] . Recently, the contribution of TLR3 to disease progression has been reported in a mouse model of SE-induced epilepsy [65] .
Clinical studies: treatments targeting IL-1R/TLR signalling in human drug-resistant epilepsies
Proof-of-concept clinical trials and case report studies have been developed using drugs targeting IL-1R1/ TLR4 signalling (Table 3) . A 6-week phase IIA randomized, double-blind, placebo-controlled study was completed in drug-resistant focal onset epilepsy patients receiving VX-765 (n = 48) or placebo (n = 12). Post hoc analysis showed a delayed beneficial effect of VX-765 that persisted for some time after drug discontinuation [66] . A recent case report described that the use of anakinra drastically improved seizure control in a child with super-refractory SE secondary to febrile infection-related epilepsy syndrome (FIRES) [67] . The add-on therapy of anakinra was also effective in controlling epileptic activity and improving cognitive skills in four adolescents with drug-resistant epilepsy [68] .
These encouraging results support further clinical investigations. Clinical studies would greatly benefit from the identification of noninvasive biomarker(s) reflecting the activation of the IL-1R/TLR signalling (see next paragraph). This would allow patient stratification to test the potential therapeutic utility of candidate drugs and for designing affordable and adequately powered antiepileptogenesis trials.
Biomarker role of IL-1b and HMGB1 in epilepsy
IL-1b and HMGB1 levels in blood, which may reflect brain intrinsic events involved in disease development, were measured to investigate the potential biomarker value of these molecules. Controversial findings relate to measurements of IL-1b level in serum of epilepsy patients or healthy controls likely due to instability and very short half-life of this cytokine (reviewed in [26] ). However, recent evidence highlighted the potential biomarker value of cerebrospinal fluid (CSF)/serum IL-1b ratio measured during the first week after neurotrauma for predicting the risk to develop post-traumatic epilepsy in patients [69] .
As a potential biomarker HMGB1 fulfils many important criteria, including its stability in blood. In a rat model of SE-induced epileptogenesis, blood HMGB1 levels increased before the onset of spontaneous seizures and mirrored the HMGB1 alterations detected in the brain [20] . Notably, blood HMGB1 levels prospectively identified animals developing epilepsy [20] . Consistent with animal studies, drug-resistant epilepsy patients had significantly higher blood HMGB1 levels than both healthy controls and patients with drugcontrolled epilepsy [20] . Moreover, in a pilot study performed in with newly diagnosed epilepsy patients, the pathological disulphide HMGB1 isoform was increased in blood, and its persistence was associated with seizure relapse [20] . Taken together, these data suggest that HMGB1 is a potential biomarker for epileptogenesis and drug-resistant epilepsy which could be used to increase the sensitivity and precision of the available clinical indicators.
COX-2 signalling
Cyclooxygenase-2, also known as prostaglandin-endoperoxide synthase 2 or prostaglandin G/H synthase, is an enzyme responsible for the biosynthesis of prostaglandins, which are lipid metabolites that are involved in several physiological and pathological processes, including inflammation. COX-2 catalyses the conversion of arachidonic acid into prostaglandin G2 (PGG 2 ) and then peroxidase activity reduces PGG 2 -PGH 2 . PGH 2 is rapidly converted by specific synthetases to prostaglandins PGD 2 , PGE 2 , PGF 2a , prostacyclin I2 (PGI 2 ), and thromboxane A2 [70] . In recent years, many studies in the field of epilepsy focused on COX-2 since it is an important mediator of neuroinflammation.
Expression studies
Experimental models COX-2 is constitutively expressed at low to moderate levels in somata and dendrites of excitatory hippocampal neurons, and is induced after brain injury, such as SE, stroke, traumatic brain injury, CNS infection, as well as during seizure recurrence [23, [70] [71] [72] . The level of COX-2 mRNA in the adult rodent hippocampus was rapidly (<1 h) and persistently increased for hours to days after SE induction [11, [73] [74] [75] [76] or after hippocampal kindling in which seizures were induced by repetitive stimulations [77] . Similarly, COX-2 protein expression was induced within 2 h until a few days after SE [15, 76, [78] [79] [80] [81] , as well as after kindling [82, 83] . In PN21 rats, COX-2 protein increased almost fivefold at 24 h after KAinduced SE, and returned to the control level within 3 days [84] . In PN9 rats, however, COX-2 expression remained unchanged compared to controls at all timepoints studied (6 h, 24 h, 7 days). This suggests that COX-2 induction by epileptogenic insults is agedependent, and the mechanisms regulating its expression and functions are still immature in PN9 rats, which is in accordance with the increase in COX-2 expression during postnatal development in rats [84] .
Prominent expression changes of genes involved in prostaglandin synthesis and regulation, including COX-2, were observed in the hippocampus and entorhinal cortex after electrically induced SE in rats [11, 81] . Interestingly, most genes showed a biphasic response and were up-regulated in the acute phase (1 day after SE), returned to baseline in the latent phase (1 week after SE) and were again up-regulated in the chronic phase (3-4 months after SE) when the animals displayed spontaneous recurrent seizures (SRS) [11, 81] . Similarly, PGE 2 levels in rat hippocampus were increased during the acute and chronic phase after SE [81, 85] , as well as after hippocampal kindling [77] . Immunohistochemistry confirmed the up-regulation of COX-2 protein in granule and pyramidal layers of hippocampus and outer pyramidal and granule layers of neocortex after kindling [82] and in somata and dendrites of hippocampal pyramidal and granule cells and in the molecular layer of the dentate gyrus during the acute phase after SE [81] . Up-regulation of neuronal COX-2 was also found in the piriform cortex and the superficial cortical layers [81] . During the latent period, COX-2 protein expression was reduced when compared to the acute phase, thus resembling the expression in control rats [81] . During the chronic epileptic phase, COX-2 up-regulation was evident in the CA3 and in granule cells although to a lesser extent than early after SE [81] . COX-2 protein expression was also rapidly increased (<1 h) mainly in principal hippocampal neurons after pilocarpine-induced SE in mice, peaking between 4 and 12 h then it gradually subsided by 10 days after SE [76] .
Human studies Strong immunohistochemical COX-2 expression was observed in CA3 and CA1 hippocampal neurons as well as in astrocytes within these regions and in the hilus of the dentate gyrus in brain specimens from patients with drug-resistant TLE and HS. This result was also confirmed by western blot analysis [86] , but not in patients without HS [81, 87] .
Role of COX-2 signalling in seizure mechanisms
Seizures induce COX-2 in hippocampal principal neurons within hours [88, 89] , partly via a pathway involving NMDA receptors [88] . SE-induced COX-2 immunoreactivity in adult rats has been co-localized with c-Fos in the olfactory-limbic regions, the lateral and basolateral amygdala, and piriform cortex [74] . This suggests that an interconnected neural network is activated during seizure activity, and that COX-2 is induced in these brain regions.
To study the involvement of COX-2 in seizures in vivo, acute seizures were evoked by PTZ and selective COX-2 inhibitors were administered before or after PTZ injection (Table 1) . Celexocib administered 60 min before PTZ-induced seizures delayed the onset and decreased the duration of the convulsive seizure in rats, which could be reversed by intracerebroventricular injection of PGE 2 [90] . Furthermore, combining intracerebral injection of PGE 2 with a subconvulsant dose of PTZ caused seizures, supporting a role for PGE 2 in setting seizure's threshold [90] . Similarly, nimesulide or rofecoxib administered 45 min prior to PTZ injection in mice delayed seizure onset, decreased seizure duration [91] and increased PTZ seizure threshold [92] . However, a 5 day prophylactic treatment with rofexocib did not have any effect on PTZ-induced seizures in mice [83] . Furthermore, celecoxib administered 30-120 min before or 10-20 min after KA, or NS-398 administered 30 min before KA, enhanced seizure severity and mortality [93] [94] [95] . Likewise, nimesulide given 1 h before or 10-20 min after KA-induced seizures increased the number of seizures and animal mortality [94, 96] , but did not lead to adverse effects when administered 6-8 h after KA [96] . These studies suggest that time of drug treatment vs. the convulsive challenge may determine seizure suppressive vs. seizure aggravating effects. In addition, other factors such as animal strain/species, type of stimulation, route of drug administration, type of drug used, as well as the level of prostaglandins at the time of drug intervention may be important.
Role of COX-2 signalling in epileptogenesis
Selective COX-2 inhibitors were used in animals exposed to chemical or electrical kindling or to SE (Table 2) . A 5-day prophylactic treatment with rofexocib did not have any effect on PTZ-kindling in mice [83] . In contrast, nimesulide administered before PTZ injection reduced kindling development [97] . It also reduced rapid hippocampal-kindling development evoked by electrical stimulation of the angular bundle [77, 82] . Furthermore, the afterdischarge duration was decreased in COX-2 knockout mice [77] . Since COX-2 and cytosolic phospholipase A2, an enzyme that catalyses the synthesis of COX-2 substrate arachidonic acid, were induced in the hippocampus and neocortex after kindling [82] , these data suggest that arachidonic acid is actively converted into prostaglandins during epileptogenesis and that COX-2 plays a pro-epileptogenic role.
Selective COX-2 inhibitors were also administered before or after SE to study their effects on the development of spontaneous seizures. Celexocib treatment started 1 day after pilocarpine-induced SE and continued for 28 days, reduced the frequency and duration of spontaneous seizures [80] . A 18-day parecoxib treatment started immediately after termination of pilocarpine-induced SE prevented the increase in PGE 2 and reduced the generalization of spontaneous seizures but not their frequency and duration, indicating a diseasemodifying effect [98] . Similarly, a 7-day treatment with the selective COX-2 inhibitor SC-58236, starting 4 h after electrically induced SE did not affect frequency and duration of spontaneous seizures [81] . When SC-58236 treatment was started 1 day before SE and continued for 3 days it induced adverse effects by increasing rat mortality during the first 2 weeks after SE [99] . When SC-58236 treatment was started in the chronic phase, the number of seizures in the second week of the treatment increased by 50% [99] . Therefore, the administration of COX-2 inhibitors before SE, independent of the model used, may lead to adverse effects, whereas the administration after SE may reduce spontaneous seizures depending on the animal model. In summary, the use of COX-2 inhibitors in SE models reveal a complex role of COX-2 in epileptogenesis, as also discussed in the previous paragraph pertaining to acute seizures.
The results from COX-2 inhibitors in SE models suggest that the targeting of downstream effector molecules in the COX-2 signalling cascade may be a safer therapeutic approach [100] . In this respect, antagonists of prostaglandin receptors, particularly for the EP1 and EP2 receptor, showed promising results [76] . EP1 receptor knockout mice had reduced incidence of KAinduced SE, and hippocampal neurodegeneration and inflammation were also reduced [70] . Systemic pretreatment with the EP1 antagonist SC-51089 only moderately decreased seizure severity without affecting the seizure threshold in amygdala-kindled mice [101] , indicating that the EP1 antagonist alone may not afford sufficient antiseizure effects. Antagonizing the EP2 receptors with small molecules penetrating the BBB after systemic injection reduced neuronal injury in hippocampus when administered in mice beginning 1 h after termination of pilocarpine-induced SE [102] . Furthermore, a selective EP2 receptor antagonist in the same model reduced mortality, brain inflammation, BBB opening, and was neuroprotective in the hippocampus [103] . A wide therapeutic window for EP2 receptor blockade was identified, and specific antagonists were shown to reduce SE-induced delayed mortality and functional morbidity in mice [76] , to be neuroprotective, accelerate functional recovery [104] , and prevent memory impairment [105] in rats after diisopropyl-fluorophosphate (a soman analog)-induced SE. Although EP1 and EP2 receptors seem promising targets, further studies are required to study the effect of their antagonism on epileptogenesis.
Clinical studies: treatments targeting COX-2 signalling in human drug-resistant epilepsies Until now, there are no clinical studies using specific COX-2 inhibitors in epilepsy [71] . Due to side effects, many of these inhibitors (e.g. celecoxib, rofexocib, valdecoxib, parecoxib, lumiracoxib, etoricoxib) have been withdrawn from the market, failed to get approval, or are listed as 'on alert' by the U.S. Food and Drug Administration and by the Australian Therapeutic Goods Administration, although some of them still maintain their license in the European Union [71] . However, nonsteroidal anti-inflammatory drugs (which are nonselective COX inhibitors that reduced the onset, frequency and duration of SRS in preclinical epilepsy models [106, 107] ) were investigated in patients with epilepsy (Table 3) . A randomized, placebo-controlled trial in 230 children failed to demonstrate a preventive effect of ibuprofen treatment during fever on the number of febrile seizure recurrence [108] . In patients with Sturge-Weber syndrome, 8 of 9 patients were seizurefree for 1 year or more, after a 6-year period of continuous or intermittent treatment with aspirin [109] . In a retrospective study, including 58 patients with SturgeWeber syndrome, 91% of the subjects on low-dose aspirin had good final seizure scores (either no seizures in the last 6 months, or breakthrough seizures within the last 6 months, but no monthly seizures). This was in an improvement from 83% subjects assessed at the first seizure score [110] . In another study, the effects of a low dose of aspirin were investigated in 34 patients with Sturge-Weber syndrome and a significant reduction in both self-reported seizure frequency and strokelike episodes was reported [111] . In a retrospective study, including 23 adults with focal onset epilepsy who took aspirin daily, whereas undergoing elective video-EEG monitoring, less seizures were observed as compared to 23 patients that were not taking aspirin. Furthermore, higher aspirin doses were correlated with fewer seizures during the monitoring period [112] . However, these data should be interpret with caution, as stated by the authors: 'The associations are modest and borderline insignificant, the study remains underpowered, and the study group is narrow, tertiary and not designed to address aspirin efficacy in seizure control. However, given that aspirin is of relatively low risk, ubiquitous, and inexpensive, these data justify further studies of its potential as an adjunctive medication in adult patients with partial epilepsy. Such a study would best be assessed with a randomized, placebo-controlled, double-blind method'.
Biomarker role of COX-2 signalling in epilepsy COX-2 induction may be a useful marker for neuronal pathway activation associated with seizures [74] , and possibly a biomarker for epileptogenesis. However, to the best of our knowledge, there are no studies investigating this aspect. For clinical use, this task requires the development of a COX-2 specific marker, or a downstream effector molecule such as PGE 2 , that can be used for neuroimaging. Furthermore, it may be worthwhile to investigate whether PGE 2 that is released in the brain after SE or recurrent seizure activity [81, 85, 113] can be measured in blood and serve as biomarker for epileptogenesis and/or ictogenesis.
Other potential targets
Tumour necrosis factor alpha Tumour necrosis factor alpha mRNA in rodent brain is rapidly induced during limbic seizures, and its expression declines to basal levels within 72 h from SE onset [10, 12, 114, 115] . Immunohistochemical analysis of TNF-a in rodent hippocampus showed cytokine expression in glial cells and in the BBB endothelium [10, 116] . A concomitant progressive reduction in TNF-a receptor type 2 (TNFR2) in neurons vis-a-vis with an increase in TNFR1 in neurons and astrocytes was detected [54] ; western blot analysis showed changes concordant with immunohistochemical findings [117] . TNF-a was induced in astrocytes and neurons in brain specimens from TLE and tuberous sclerosis patients, whereas it was below detection level in autoptic control tissue [54, 118] . Receptor analysis confirmed the changes observed in experimental models [54] .
TNF-a injected into the mouse hippocampus significantly reduced seizures by activating TNFR2 [119] , whereas it promoted seizures by activating TNFR1 [120] . Transgenic mice with low/moderate overexpression of TNF-a in astrocytes showed decreased susceptibility to seizure [119] , whereas mice with high TNF-a overexpression develop signs of neurological dysfunction, including seizures [121] . These findings highlight the importance of the brain concentration of this cytokine and the receptor subtype predominantly expressed for determining the final outcome on seizures. The functional interactions between TNF-a and glutamate (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and NMDA) receptors or GABA A receptors may be a key molecular mechanism for controlling neuronal excitability [122] [123] [124] .
A pilot clinical study evaluated the efficacy of a monoclonal anti-TNF-a antibody (adalimumab) in Rasmussen's encephalitis (Table 3 ) [125] . The treatment lead to seizure improvement in 5 of 11 patients and was associated with stabilization of functional deficit in three patients [125] .
Complement system
The complement system belongs to the innate immune response and mediates a potent inflammatory response. More than 30 proteins that interact in a finely regulated manner are activated to destroy invading bacteria and for preventing the deposition of immune complexes in normal tissue [126] . The CNS constitutively expresses complement proteins [127] . Various complement proteins are overexpressed in human as well as experimental epilepsy [11, [128] [129] [130] . Moreover, a genetic association of C3 in the development of epilepsy in patients with TLE and a history of febrile seizures has been found, which implicates a role of the complement system in TLE [129] .
Animal studies have shown that the complement system contributes to seizures. C3-deficient mice develop significantly fewer behavioural seizures following Theiler's virus infection than wild-type mice [131] . Kindling development was delayed in C6-deficient rats [132] . Sequential infusion of individual proteins of the membrane attack pathway (C5b6, C7, C8, and C9) into the hippocampus of awake, freely moving rats induced both behavioural and electrographic seizures as well as cytotoxicity [126] . The onset of seizures occurred during or shortly after the infusion of C8/C9 [126] . These findings imply that targeting the complement could be a novel therapeutic approach in epilepsy. In support, a C5ar1 antagonist (PMX53) was found to be anticonvulsant in the 6 Hz and corneal kindling model (an acute seizure model) and in the intrahippocampal KA chronic seizure model (Table 1 ) [133] . Furthermore, inhibition of C5ar1 after pilocarpine-induced SE, or its genetic deletion, lessened seizure power, protected hippocampal neurons from degeneration and reduced SEassociated mortality [133] . The limitation of PMX53 is its short half-life [133] , therefore, new brain-permeable C5ar1 inhibitors with an improved pharmacokinetic profile need to be developed.
Currently, a C5a antibody, eculizumab, is used in the clinic for a rare immunological condition, paroxysmal nocturnal hemoglobinuria [134] , but this drug has not been used in patients with epilepsy.
Finally, complement factors may also serve as biomarkers for epileptogenesis or ictogenesis since increased C3 serum levels were found in patients with epilepsy [135] .
Chemokines
The expression of various chemokines and their cognate receptors is increased both in human and experimental epileptogenic brain tissue in neuronal, glial and endothelial cells, as well as in infiltrating leucocytes ( [136, 137] ; reviewed in [138] ).
Beside their role of chemotactic molecules controlling leucocyte trafficking across the BBB (reviewed in [138] ), there is emerging evidence indicating that chemokines can represent a new class of neuromodulators, since they modulate voltage-gated ion channels (reviewed in [139] ) and regulate neurotransmitter release (reviewed in [139, 140] ). In this respect, fractalkine [or chemokine C-X3-C motif ligand 1 (CX3CL1)] acts as a positive modulator of GABA A receptor in human TLE brain specimens by reducing the GABA A use-dependent desensitization (i.e. rundown) [136] . This effect may be mediated by phosphorylation of one or more GABA A subunits, thus leading to a 'stabilization' of the receptor. The up-regulation of fractalkine receptor in epileptogenic tissue may therefore represent an homeostatic attempt to reduce hyperexcitability by promoting GABA receptor function.
The chemokine C-C motif ligand 2 (CCL2) and its receptor C-C chemokine receptor 2 (CCR2) are elevated in brain tissue of patients with drug-resistant epilepsy as well as in a mouse epilepsy model ( [137] ; reviewed in [138, 141] ). In mice with chronic seizures, the systemic administration of either a CCL2 transcription inhibitor (bindarit) or a selective antagonist of the CCR2 receptor (RS102895), or the intracerebral injection of an anti-CCL2 antibody, abrogated the spontaneous seizure worsening provoked by a systemic inflammatory challenge induced by LPS (Table 1 ) [137] . Notably, a CCL2 polymorphism resulting in higher level of CCL2 production, was associated with a greater susceptibility to drug-resistant epilepsy [142] .
The expression of the chemokine receptor CCR5 was reduced in rats using a SV40-derived vector carrying an interfering RNA against CCR5. Vector delivery in the bone marrow before inducing SE, decreased CCR5 expression in circulating leucocytes and protected animals from seizures, BBB leakage, brain inflammation, and also facilitated physiological neurogenesis [143] . These data suggest that chemokines may act as mediators linking peripheral inflammation with neuronal hyperexcitability.
Changes in chemokines levels were described in biofluids in epileptic conditions. A marked upregulation of chemokines in the CSF of patients with FIRES was reported [144] . Notably, the ratio thymus and activation regulated chemokine (CCL17)/soluble intracellular adhesion molecule 5 in plasma accurately distinguished between controls and drug-resistant epilepsy patients, thus suggesting a candidate biomarker for drug-resistance [145] .
Conclusions
Prominent changes in several immune/inflammatory pathways, such as IL-1R1/TLR4, COX-2, TNF-a, complement and chemokines have been reported within epileptogenic lesions in preclinical and clinical studies. Since these pathways seem critically involved in ictogenesis and epileptogenesis, specific drugs or interventions targeting them may decrease established seizures or display antiepileptogenesis and disease modification effects (Figure 2 ). Specific anti-inflammatory drugs have shown significant therapeutic effects and a safe profile in proof-of-concept clinical studies, thus prompting further investigations (Figure 2 ). Future studies should also focus on validating potential noninvasive biomarkers of epilepsy which could be used to increase the sensitivity and precision of clinical indicators. (Figure 1 ). Inhibition of these pathways (in red) favourably affects seizure susceptibility and/or epileptogenesis in preclinical models (top row), as well as reduce seizure occurrence in various epilepsy-related pathologies in human (bottom row), suggesting that they may represent novel therapeutic targets.
